<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095766</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1488</org_study_id>
    <nct_id>NCT05095766</nct_id>
  </id_info>
  <brief_title>Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis</brief_title>
  <acronym>ITIRR</acronym>
  <official_title>Differentiation Between Radionecrosis and Tumor Recurrence for Post-stereotactic Radiosurgery Follow-up by Pharmacokinetic Analyses in Perfusion MRI and Positron Emission Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During gamma scalpel treatment of brain tumors and metastases, a follow-up magnetic resonance&#xD;
      imaging (MRI) scan is performed. The radiologist who reviews the MRI assesses whether there&#xD;
      is an increase in signal at the tumor site. This increase potentially indicates that the&#xD;
      treatment was not effective. However, in 25% of cases (one in four people), this signal&#xD;
      enhancement is not due to ineffective treatment, but to inflammation (swelling/damage) and&#xD;
      tissue death around the tumor. This is why when an increase in signal is detected, additional&#xD;
      follow-up is essential. The standard additional follow-up has an accuracy of about 83%.&#xD;
&#xD;
      This is an observational study on patients with brain metastatis comparing MRI alone or&#xD;
      combined to PET-FET to improve accuracy of diagnosis of metastasis recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2017</start_date>
  <completion_date type="Anticipated">November 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of novel MRI method with current MRI exam method</measure>
    <time_frame>Following MRI exam</time_frame>
    <description>In the context of differentiating radionecrosis and recurrence of metastasis: Is our new method better than the actual standard of care in Sherbrooke?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of DCE-MRI method with FET PET</measure>
    <time_frame>Following MRI exam</time_frame>
    <description>In the context of differentiating radionecrosis and recurrence of metastasis: is one better than the other? And Can DCE-MRI and FET PET be combined to differentiate between recurrence/radionecrosis?</description>
  </primary_outcome>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with brain metastases undergoing MRI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female over 18 years of age;&#xD;
&#xD;
          -  Having undergone gamma knife radiosurgery for brain metastasis;&#xD;
&#xD;
          -  Presenting for a first MRI follow-up (Cohort C1);&#xD;
&#xD;
          -  Presence of one or more brain metastases with increased enhancement on follow-up MRI&#xD;
             (Cohort C2.1 and C2.2); A participant recruited for Cohort C1 could be recruited for&#xD;
             follow-up in Cohort C2.1 or C2.2 if the MRI result is ambiguous.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding;&#xD;
&#xD;
          -  Other condition that may influence the imaging result;&#xD;
&#xD;
          -  Renal impairment (&lt;30 mL/min/1.73 m2). This threshold is consistent with recent RAC&#xD;
             recommendations; Note: For participants with intermediate renal clearance (30-60&#xD;
             mL/min/1.73 m2), the total gadobutrol dose injected is set at the manufacturer's&#xD;
             recommended clinical dose. For patients with renal clearance greater than 60&#xD;
             mL/min/1.73 m2, a dose of 1.5x the normal dose is used. These dose values have been&#xD;
             approved by Dr. Chénard and are consistent with the RAC recommendations.&#xD;
&#xD;
          -  Inability to maintain supine position for the required duration (variable, depending&#xD;
             on the sequence);&#xD;
&#xD;
          -  Patients who have previously received full brain irradiation;&#xD;
&#xD;
          -  Patients who are claustrophobic and cannot tolerate insertion into the MRI scanner;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rejean Lebel, PhD</last_name>
    <phone>819-821-8000</phone>
    <phone_ext>11870</phone_ext>
    <email>Rejean.Lebel@USherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Lavallée, TIM</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12887</phone_ext>
    <email>Eric.lavallee2@usherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie-CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rejean Lebel, PhD</last_name>
      <phone>819-821-8000</phone>
      <phone_ext>11870</phone_ext>
      <email>Rejean.Lebel@USherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Eric Lavallé, TIM</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12887</phone_ext>
      <email>Eric.lavallee2@usherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Lepage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Chénard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Éric Turcotte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Mathieu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Marc Jodoin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tal Arbel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Radiofrequency</keyword>
  <keyword>Radionecrosis</keyword>
  <keyword>Tumor recurrence</keyword>
  <keyword>Post-stereotactic surgery</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>CT scan</keyword>
  <keyword>18F-fluoroethyl-tyrosine</keyword>
  <keyword>Perfusion MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

